Skip to content

A prospective multicenter clinical registry study of transvenous approach (TVE) for the treatment of cerebral arteriovenous malformations

A prospective multicenter clinical registry study of transvenous approach (TVE) for the treatment of cerebral arteriovenous malformations

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100659
Enrollment
Unknown
Registered
2025-04-14
Start date
2025-04-18
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral arteriovenous malformations

Interventions

Transvenous interventional embolization treatment group:Transvenous embolization therapy

Sponsors

The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosis of BAVM: Diagnosis of BAVM is confirmed by MR/CTA/DSA. 2.Age= 13 years old = 60 years old; 3. single or two dominant venous drainage; 4.The diameter of the deformity during TVE< 3.5cm; 5.Obtain informed consent signed by the research participant or his/her legal guardian or representative.

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation; Premenopausal female patients with positive urine or plasma pregnancy test (no documented history of surgical sterilization); 2.Patients with bilateral mydriasis at the time of admission; 3.Combined tumors, bleeding disorders or other known serious underlying diseases (such as chronic obstructive pulmonary disease, multi-organ insufficiency, severe diabetes, cardiac insufficiency and chronic kidney disease, etc.); 4.mRS = 3 points due to intracranial hemorrhage or neurological dysfunction before treatment 5.Radiological image confirmed with ruptured aneurysm; 6.The bAVM is too diffuse; 7.Platelet count 1.4, or elevated TP or ATPP; Patients requiring long-term anticoagulation; 9.Other conditions that are not suitable for enrollment (determined by two doctors); 10. Patients participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Good prognosis rate of neurological function after 180 days (6 months) of enrollment;

Secondary

MeasureTime frame
Immediate complete occlusion rate postoperatively;BAVM occlusion rate of cerebral angiography at 6 months after surgery;Stroke events within one week of enrollment to the end of embolization;Stroke events at clinical follow-up one week after embolization to 1 year;

Countries

China

Contacts

Public ContactJianmin Liu

The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)

liu118@vip.163.com+86 139 0178 0638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026